Pulmatrix Stock Cash And Equivalents
| PULM Stock | USD 5.48 0.07 1.29% |
Fundamental analysis of Pulmatrix allows traders to better anticipate movements in Pulmatrix's stock price by examining its financial health and performance throughout various phases of its business cycle.
Pulmatrix | Build AI portfolio with Pulmatrix Stock |
Pulmatrix Company Cash And Equivalents Analysis
Pulmatrix's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Pulmatrix Cash And Equivalents | 42.91 M |
Most of Pulmatrix's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pulmatrix is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Pulmatrix has 42.91 M in Cash And Equivalents. This is 94.77% lower than that of the Pharmaceuticals sector and 90.4% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 98.41% higher than that of the company.
Pulmatrix Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pulmatrix's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pulmatrix could also be used in its relative valuation, which is a method of valuing Pulmatrix by comparing valuation metrics of similar companies.Pulmatrix is currently under evaluation in cash and equivalents category among its peers.
Pulmatrix Fundamentals
| Return On Equity | -0.93 | ||||
| Return On Asset | -0.32 | ||||
| Operating Margin | (5.07) % | ||||
| Current Valuation | 10.24 M | ||||
| Shares Outstanding | 3.65 M | ||||
| Shares Owned By Insiders | 0.66 % | ||||
| Shares Owned By Institutions | 8.85 % | ||||
| Number Of Shares Shorted | 25.38 K | ||||
| Price To Earning | (1.30) X | ||||
| Price To Book | 2.73 X | ||||
| Price To Sales | 10.29 X | ||||
| Revenue | 7.81 M | ||||
| Gross Profit | 1.89 M | ||||
| EBITDA | (6.71 M) | ||||
| Net Income | (9.56 M) | ||||
| Cash And Equivalents | 42.91 M | ||||
| Cash Per Share | 12.67 X | ||||
| Total Debt | 996 K | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 8.19 X | ||||
| Book Value Per Share | 1.96 X | ||||
| Cash Flow From Operations | (10.72 M) | ||||
| Short Ratio | 0.44 X | ||||
| Earnings Per Share | (3.40) X | ||||
| Target Price | 10.0 | ||||
| Beta | 1.45 | ||||
| Market Capitalization | 19.76 M | ||||
| Total Asset | 9.94 M | ||||
| Retained Earnings | (297.16 M) | ||||
| Working Capital | 8.99 M | ||||
| Current Asset | 8.34 M | ||||
| Current Liabilities | 4.11 M | ||||
| Net Asset | 9.94 M |
About Pulmatrix Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pulmatrix's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pulmatrix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pulmatrix based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Pulmatrix Piotroski F Score and Pulmatrix Altman Z Score analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.